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by various factors: allergens, drugs, respiratory infection, 
dust, cold air, exercise, emotions, occupational stimuli, 
chemicals, histamine, etc.[1] Histological examination of 
bronchial biopsies and cytology of bronchoalveolar lavage 
fluid (BALF) have demonstrated infiltrating inflammatory 
cells in the tracheobronchial mucosa and airway lumen of 
patients with asthma, even those with mild disease.[2,3] The 
influx of inflammatory cells is accompanied by marked and 
characteristic pathophysiological changes to the airways, 
including thickening of the airway wall, which have been 
implicated in the restriction of airflow and the development 
of airway hyperresponsiveness.[3] The disease statistics 
clearly necessitates the increasing need for drugs targeting 
the mechanisms involved in eosinophil and neutrophil 
INTRODUCTION
Asthma is one of the most common disorders encountered 
in clinical medicine in both children and adults, characterized 
by inflammation of the airway that is central to airway 
dysfunction. It is known that asthma can be triggered 
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ABSTRACT
The present investigation was undertaken to evaluate the bronchodilating effect and bronchial hyperreactivity 
of alcoholic extract of Taxus baccata Linn. (AET) leaves in experimental animals. Bronchodilator activity of AET 
was studied on the histamine and acetylcholine aerosol induced bronchospasm in guinea pigs and bronchial 
hyperreactivity was studied on bronchoalveolar lavage fluid (BALF) in the egg albumin sensitized guinea pigs 
and by histopathological studies. In vitro mast cell stabilizing activity was studied using compound 48/80 as a 
degranulating agent. Treatment with AET (200 and 400 mg/kg, p.o., for 7 days) showed significant protection 
against histamine and acetylcholine aerosol induced bronchospasm in guinea pigs. Significant decrease in 
the total leukocyte and differential leukocyte count in the BALF of the egg albumin sensitized guinea pigs was 
observed by administration of  AET (200 and 400 mg/kg, p.o., for 15 days).  AET dose dependently protected the 
mast cell disruption induced by compound 48/80. These results suggest that  AET not only has bronchodilating 
activity but also decreases bronchial hyperreactivity by decreasing the infiltration of inflammatory cells in the 
airway and inhibiting the release of histamine like mediators from the mast cell by stabilizing it.
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activation and accumulation, for the management of 
asthma. Glucocorticosteroids are the only drugs currently 
available that effectively reduce airway inflammation in 
asthma.[4] 
As a result, there is high prevalence of usage of 
complementary and alternative medicines for treatment 
of this disease.[5] Ayurveda, an ancient system of Indian 
medicine, has recommended a number of drugs from 
indigenous plant sources for the treatment of bronchial 
asthma and allergic disorders.[6] Taxus baccata Linn. 
(Taxaceae) is an evergreen tree, usually 6 m in height and 
1.5–1.8 m in width, found in the temperate Himalayas 
at an altitude between 1800 and 3300 m and in the hills 
of Meghalaya and Manipur at an altitude of 1500 m.[7] 
T. baccata has been used in the Ayurvedic system for the 
treatment of cancer, diarrhea, asthma, hemoptysis and 
also used as carminative, expectorant, stomachic, etc.[8]
T. baccata leaves are reported to be used in traditional 
medicine as abortifacient, antimalarial, antirheumatic 
and for bronchitis,[9-11] and dried leaves and barks are 
used against asthma.[12] Anticancer,[13] anti-inflammatory 
and antinociceptive,[14] antifungal,[15] antimycobacterial[16] 
activity of T. baccata has been reported. Many Ayurvedic 
practitioners prescribe decoction of leaves of T. baccata 
for the treatment of asthma. However, no scientific 
studies have been carried out to investigate anti-asthmatic 
effect in the form of bronchorelaxation and inhibition of 
bronchial hyperreactivity of leaves of T. baccata. In present 
study, the anti-asthmatic activity of  AET was evaluated 




Compound 48/80 was purchased from Sigma-Aldrich 
Chemical Co. (Bangalore, India). Acetylcholine, egg 
albumin and other chemicals were purchased from S. 
D. Fine Chem. Ltd. (Mumbai, India) and histamine was 
purchased from Himedia Laboratories Pvt. Ltd. (Mumbai, 
India). Ketotifen was obtained as gift sample from Elysium 
Pharmaceutical Ltd. (Baroda, India). All other chemicals 
used were of analytical grade.
Plant material
Dried leaves of T. baccata were purchased from a commercial 
supplier of Mumbai, India. The plant was authenticated by 
Prof. Minoo Parabia, Head of Department of Bioscience, 
Veer Narmad South Gujarat University, Gujarat, India, 
where a plant specimen has been deposited with the no. 
HMG/0404/2007.
Preparation of extract
The leaves were reduced to coarse powder and macerated 
with alcohol (ethanol) for 48 hours, filtered and filtrate 
was evaporated under reduced pressure to obtained 
brown crystalline powder. The extract was stored in cool 
and dry place and used for pharmacological evaluation 
(alcohol extractive value 4.5% w/w). After obtaining 
the dry extract, qualitative preliminary phytochemical 
screening was performed to find out the presence of 
various phytochemicals.[17] For pharmacological evaluation, 
the extract was dissolved in distilled water prior to its use.
Experimental animals
Wistar rats (175–200 g) and guinea pigs (400–600 g) of either 
sex, housed in standard conditions of temperature (22 ± 
2°C), relative humidity (55 ± 5%) and light (12 hours light/
dark cycles), were used. They were fed with standard pellet 
diet and water ad libitum. In addition to pellet diet, the guinea 
pigs were supplemented with Lucerne. The experimental 
protocol was approved by Institutional Animal Ethical 
Committee as per the guidance of CPCSEA, Ministry of 
Social Justice and Empowerment, Government of India 
(Protocol No. Project 5005). A minimum of six animals 
were used in each group. Throughout the experiments, the 
animals were processed according to the suggested ethical 
guideline for the care of laboratory animals.
Acute toxicity study
Acute toxicity study was performed on female albino rats 
according to Organization for Economic Cooperation 
and Development-425 (OECD-425) guideline. Animals 
were observed for the next 14 days. There was no sign 
of changes in behavioral and autonomic profiles and any 
sign of toxicity or mortality up to a dose of 2000 mg/kg.
Histamine and acetylcholine aerosol induced 
bronchospasm in guinea pigs
Experimental bronchial asthma was induced in guinea 
pigs by exposing them to histamine and acetylcholine 
aerosol.[18] Guinea pigs were selected and divided into four 
groups, each containing six animals, out of which groups 
I and group II were exposed to 0.1% w/v of histamine 
dihydrochloride aerosol and group III and group IV were 
exposed to 0.5% w/v of acetylcholine bromide aerosol in 
histamine chamber (Inco Ltd., Ambala, India). The animals 
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exposed to histamine and acetylcholine aerosol showed 
progressive dyspnea. The end point preconvulsion dyspnea 
(PCD) was determined from the time of aerosol exposure 
to the onset of dyspnea leading to the appearance of 
convulsion. As soon as the PCD commenced, the animals 
were removed from chamber and placed in fresh air. This 
time of PCD was taken as day 0 value. The guinea pigs of 
group I and group III were treated with the  AET 200 mg/
kg, p.o. and group II and group IV animals were treated 
with 400 mg/kg, p.o., once a day for 7 days, after aerosol 
exposure on day 0. On the 7th day, 2 hours after the last 
dose, the time for the onset of PCD was recorded as on 
day 0. The percentage increase in the time of PCD was 
calculated using following formula:[19]










where T1 = time for PCD onset on day 0, T2 = time for 
PCD onset on day 7.
Studies on BALF in egg albumin sensitized guinea 
pigs[20]
Guinea pigs were selected and divided into five groups, 
i.e., group I (control: distilled water 10 ml/kg); group II 
(sensitized); group III (Sensitized + prednisolone 5mg/
kg, i.p.), group IV (sensitized + T. baccata 200 mg/kg, p.o.); 
and group V (sensitized + T. baccata 400 mg/kg, p.o.), each 
containing six animals. The guinea pigs of group II, group 
III, group IV and group V were sensitized with egg albumin 
(1 ml, 10% w/v, i.p.) on the 1st day. The animals of group 
III were dosed once daily for 15 days with prednisolone 5 
mg/kg, while group IV and group V animals were dosed 
once daily for 15 days with  AET. Two hours after the last 
dose of drug administration (on 15th day), all the animals 
of group II, group III, group IV and group V were again 
challenged with egg albumin (0.5 ml, 2% w/v, i.v.) through 
saphenous vein. After 3 hours of administration of egg 
albumin or just prior to death of animals, whichever 
was earlier, the trachea was immediately cannulated after 
anesthetization and the airways lavaged with saline at 25°C 
(two aliquots of 1 ml/100 g body weight). Bronchoalveolar 
cells were collected in two successive lavages using saline 
and recovered through a tracheal cannula. The BALF was 
stored on ice and total WBC cell counts were performed 
using a light microscope. Dilutions of lavage fluid (1 in 10) 
were made in saline, and differential WBCs were counted by 
light microscopy stained with Leishman’s stain. At least 200 
cells were counted on each slide. Cells were differentiated 
using standard morphological criteria. All differential cell 
counts were performed blind and in randomized order at 
the end of the study. The results obtained were compared 
between control and sensitized groups and sensitized and 
treated groups.
Lung histology
The same animals of the above model, i.e., used for studies 
on the BALF, were used for the histological study of the 
lungs. Left bronchi were tied before collection of BALF 
to avoid possible traumatic damage due to BALF. The 
lungs were removed and then fixed by slowly inflating with 
buffer formalin and subsequently embedded in paraffin. 
A transverse section (2–4 µm thick) was cut from each 
of the collected lungs and stained with hematoxylin and 
eosin. Histopathology assessment under light microscope 
was performed on sections.
In vitro mast cell degranulation by compound 48/80
The effect of T. baccata on in vitro mast cell degranulation 
by compound 48/80 was studied following the method of 
Gupta and Srimal.[21] Normal saline (5 ml/kg) containing 
5 units/ml of heparin was injected in the peritoneal cavity 
of male rats (n = 6) lightly anesthetized with ether. After a 
gentle abdominal massage, the peritoneal fluid containing 
mast cells was collected in centrifuge tubes placed over 
ice. Peritoneal fluid of rats was collected and centrifuged 
at 2000 rpm for 5 min. Supernatant solution was discarded 
and the cells was washed twice with saline and resuspended 
in 1 ml of saline. All the solutions were prepared in normal 
saline.
The peritoneal cell suspension was divided into six parts, 
viz., –ve control, +ve control, reference standard (ketotifen 
10 µg/ml), AET of three concentrations, i.e., 500, 750, 
1000 µg/ml, each containing 0.1 ml of cell suspension and 
incubated at a constant temperature in a water bath at 37ºC 
for 15 min. Then, 0.1 ml of compound 48/80 (10 μg/ml) 
was added to all the samples except in –ve control and the 
suspensions were further incubated for 10 min at 37°C. The 
cells were then stained with 10% of Toluidine blue solution 
and observed under the high power of light microscope. 
The percentage granulated and percentage degranulated 
mast cells were counted. In +ve control group, compound 
48/80 was added without the addition of test agents, i.e., 
ketotifen and T. baccata, and in −ve control group neither 
compound 48/80 nor the test agents were added to correct 
for spontaneous degranulation of mast cells without any 
degranulating agent.
Statistical analysis
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± SEM and analyzed statistically using Student’s t-test to 
find out the level of significance. Data were considered 
statistically significant at minimum level of P < 0.05.
RESULTS
Acute toxicity study
AET did not produce mortality and any sign of toxicity 
up to dose of 2000 mg/kg.
Phytochemical screening
Preliminary qualitative phytochemical screening of AET 
showed the presence of lignans, flavonoids, glycosides, 
sugars, amino acids and triterpenoids.
Effect on histamine and acetylcholine aerosol induced 
bronchospasm in guinea pigs
AET significantly and dose dependently increased the time 
of PCD following histamine (P < 0.001) and acetylcholine 
(P < 0.01) aerosol induced bronchospasm in guinea pigs 
[Table 1]. Increase in the time of PCD was more against 
histamine aerosol as compared to acetylcholine aerosol, 
following administration of T. baccata leaves extract.
Effect on BALF in egg albumin sensitized guinea pigs
After 15 days, the guinea pigs were again challenged with 
egg albumin. In the BALF, significant increases in the 
total leukocyte count and differential leukocytes count 
were observed in the sensitized, i.e., group II (P < 0.001) 
animals as compared to the control, i.e., group I animals.   
AET (200 and 400 mg/kg, p.o., for 15 days) significantly 
and dose dependently decreased the total leukocyte 
count (P < 0.05) and differential leukocyte count (P < 
0.001) in group IV and group V as compared to group II   
[Table 2] animals. Prednisolone also significantly decreased 
total leukocytes count (P < 0.001) and differential 
leukocytes count (P < 0.001) compared to sensitized group.
Lung histology
Histological analysis of the lungs from non-sensitized, i.e., 
group I animals, showed normal lung histology [Figure 1a]. 
In contrast, similar to the BALF study, histological sections 
of lung tissue from group II guinea pigs exhibited airway 
inflammation, infiltration of eosinophils, lymphocytes and 
submucosal edema of the lungs, and bronchoconstriction 
shown as lumen plugging by mucus and cells [Figure 1b]. 
Treatment with prednisolone and T. baccata, i.e., group IV 
and group V animals, prevented the tissue edema, epithelial 
cell hypertrophy, infiltration of inflammatory cell, and 
airway lumen plugging, thereby decreasing inflammation 
and broncoconstriction, which led to normal lumen size 
[Figure 1c–e].
Effect on compound 48/80 induced mast cell 
degranulation
AET and ketotifen were found to significantly (P < 0.001) 
Table 1: Effect of Taxus baccata (p.o., for 7 days) 
on histamine and acetylcholine aerosol induced 
bronchospasm in guinea pigs











I- T. baccata 
(200 mg/kg)
125.8 ± 18.56 447.2 ± 25.34* 72.82 ± 3.14
II- T. baccata 
(400 mg/kg)
127.4 ± 20.32 632.7 ± 53.47* 80.67 ± 6.23
Acetylcholine aerosol 
(0.5% w/v)
III- T. baccata 
(200 mg/kg)
149.27 ± 11.23 354.5 ± 32.09# 58.73 ± 3.09
IV- T. baccata 
(400 mg/kg)
137.4 ± 23.60 438.57 ± 43.71* 67.98 ± 4.61
Values are expressed as mean ± SEM for six guinea pigs in each group, *P < 0.001, 
#P < 0.01 when compared with control group
Table 2: Effect of Taxus baccata (p.o., for 15 days) on BALF in egg albumin sensitized guinea pigs
Control Sensitized Prednisolone  
(5 mg/kg)
Sensitized + T. baccata 
(200 mg/kg)
Sensitized + T. baccata 
(400 mg/kg)
TLC/mm3 8842 ± 429 14,740 ± 670.9* 9247 ± 467.7$ 11,680 ± 313.5@ 9680 ± 248.32$
Neutrophil count/mm3 2774 ± 304.2 4100 ± 169.9* 2894 ± 189.6$ 3921 ± 287.25# 3081 ± 267.34$
Lymphocyte count/mm3 4472 ± 384.8 9130 ± 235.2* 4872 ± 328.4$ 6772 ± 343.2$ 5892 ± 327.82$
Eosinophil count/mm3 184.8 ± 14.82 506.2 ± 36.71* 278 ± 19.67$ 420.3 ± 19.45$ 337.78 ± 13.26$
Monocyte count/mm3 109.3 ± 6.28 263.1 ± 21.52* 113.6 ± 8.67$ 200.5 ± 17.08$ 153.6 ± 8.31$
Values are expressed as mean ± SEM for six guinea pigs in each group, *P < 0.001 when compared with control group; @P < 0.05, #P < 0.01, $P < 0.001 when compared with 
sensitized	group,	BALF:	Bronchoalveolar	lavage	fluid,	TLC:	Total	leukocyte	count
Patel, et al. J Young Pharm. 2011;3(1): 41-47Journal of Young Pharmacists Vol 3 / No 1  45
inhibit rat peritoneal mast cell degranulation induced by 
compound 48/80 in vitro as compared to baseline value, 
i.e., +ve control group [Table 3].
DISCUSSION
Bronchial asthma is commonly characterized by increased 
airway reactivity to spasmogens. An initial event in asthma 
appears to be the release of inflammatory mediators like 
histamine, triggered by exposure to allergens that directly 
cause acute bronchoconstriction.[22,23] In the present study, 
histamine and acetylcholine were used as spasmogens in the 
form of aerosol to cause immediate bronchoconstriction 
in the form of PCD in guinea pigs. Bronchodilating 
effect of  AET was evaluated by observing its effects at 
the time of PCD. In our study, we found that the time of 
occurrence of PCD was significantly increased, suggestive 
of bronchodilating activity following treatment with T. 
baccata against spasmogens.
Increasing evidence suggests that the frequently observed 
association between activated T lymphocytes and 
eosinophils plays a major role in the development of 
airway inflammation and in the accompanying bronchial 
hyperreactivity.[24,25] Neutrophils and monocytes play 
a pivotal role in the disease process as they are a 
source of variety of inflammatory mediators which are 
responsible for bronchial hyperresponsiveness and airway 
inflammation.[26] In association with asthma, elevated 
numbers of these inflammatory cells like eosinophils, 
neutrophils, lymphocytes, monocytes have been identified 
in various tissue compartments like blood, biopsies of 
lung tissue, in BALF and in sputum. In the present study, 
sensitization using egg albumin (1 ml, 10% w/v, i.p.) and 
then second exposure to the same antigen, i.e., egg albumin 
(0.5 ml, 2% w/v), through saphenous vein caused acute 
anaphylactic shock resembling the acute asthmatic attack 
resulting in the release of various mediators and cellular 
infiltration. Antigen challenge resulted in significant 
increase in the number of eosinophils in the BALF. 
This was accompanied by intense eosinophil infiltration, 
accumulation and degranulation in the guinea pig lungs 
as evident in histopathology study, which is consistent 
with human asthmatic lungs. In our study, we found that 
treatment with T. baccata in antigen challenged animals 
significantly inhibited antigen induced hyperreactivity 
by preventing increased infiltration of total leukocyte 
count and eosinophils count. After antigen challenge, 
airway hyperresponsiveness is supported by inflammatory 
pathology, suggesting the involvement of other mediators 
in the pathogenesis of asthma. Neutrophil numbers have 
also been reported to increase in bronchial lavage fluid 
in asthmatics, but neutrophilia is generally of shorter 
duration than eosinophilia.[27,28] This was observed in our 
result where treatment with T. baccata resulted in significant 
inhibition of antigen induced bronchial hyperreactivity 
by decreasing the neutrophil count. The participation of 
T lymphocytes in the pathogenesis of bronchial asthma 
and the accompanying bronchial hyperreactivity has 
been widely demonstrated.[25] Indeed, activated CD4+ 
T lymphocytes are found in the blood and bronchial 
Table 3: Effect of Taxus baccata on compound 48/80 




% Granulated % Degranulated
−ve	control - 91.83 ± 0.654 8.167 ± 0.654
+ve control - 26.5 ± 1.176 73.5 ± 1.176
Ketotifen 10 80.5 ± 0.957* 19.5 ± 0.957
Taxus baccata 500 41.17 ± 0.945* 58.83 ± 0.945
Taxus baccata 750 50.67 ± 0.666* 49.33 ± 0.666
Taxus baccata 1000 63.17 ± 0.945* 36.83 ± 0.945
Values are expressed as mean ± SEM, n = 6 in each group, *P < 0.001 when 
compared with baseline value, i.e., +ve control
Figure 1: Effect of Taxus baccata on the histology of lung tissue. (a) 
Control group I, (b) egg albumin sensitized group II, (c) egg albumin 
sensitized + prednisolone (5 mg/kg) group III, (d) egg albumin sensitized 
+ T. baccata treated (200 mg/kg, p.o.) group IV and (e) egg albumin 
sensitized + T. baccata treated (400 mg/kg, p.o.) group V. Prednisolone 
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lumen from asthmatics.[29] Recently, interest has been 
focused on the characterization of CD4+ T lymphocytes 
based on their repertoire of secreted cytokines and their 
possible role in the pathogenesis of allergic disorders. 
Thus, CD4+ T cells from asthmatics preferentially 
elaborate Th2-derived cytokines, such as IL-4 and IL-
5, which have been shown to enhance IgE synthesis,[30] 
and to act specifically on eosinophil survival, activation, 
and secretion of proinflammatory mediators.[31] Large 
numbers of T lymphocytes, mainly of the CD4+ subset, 
have been identified in the bronchial mucosa of antigen 
challenged guinea pigs.[32] In accordance with the above, 
the present finding shows that treatment with T. baccata 
in the sensitized animals produced a significant decrease 
in the lymphocyte count as compared to the sensitized 
animals without treatment. The predominant cells in BALF 
recovered from unchallenged guinea pigs were those of 
the monocytes. The numbers of these cells were increased 
after antigen challenge.[33] In line with the above context, 
treatment with T. baccata significantly decreased monocytes 
as compared to that in sensitized guinea pigs. The results 
of our study suggest that in guinea pig airways, antigen 
challenge induced eosinophil, neutrophil, monocyte and 
lymphocyte infiltration and activation is similar to that 
reported in human asthmatics. These show that T. baccata 
exerts its protective effect by preventing the infiltration 
of inflammatory cell, thereby decreasing the release of 
preformed inflammatory mediators, which can prevent 
the direct damage to airway, which in turn prevents airway 
hyperresponsiveness.
Various processes involved in bronchial asthma such as 
inflammatory response can explain various histopathological 
alterations observed in the biopsy of asthmatic patients. 
In asthma, chronic inflammation is responsible for the 
bronchoconstriction which leads to airway narrowing and 
decrease in the lumen size of the bronchiole.[34] This can be 
clearly seen by observing the cross-section of bronchi in the 
histopathological studies of the lung tissue. In the present 
study, the sections of the lung tissues of animals sensitized 
with egg albumin depicted marked bronchitis and severe 
bronchoconstriction. Treatment with T. baccata prevented 
the inflammation and bronchoconstriction, which led to 
normal lumen size and normal cellular structure, compared 
to antigen-sensitized guinea pigs.
Mast cell degranulation is important in the initiation of 
immediate responses following exposure to allergens.[35]
Once binding of allergen to cell-bound IgE occurs, 
mediators such as histamine; eosinophil and neutrophil 
chemotactic factors; leukotrienes C4, D4, and E4; 
prostaglandins; platelet-activating factor; and others 
are released from mast cells, which are responsible 
for the development of airway inflammation and 
bronchoconstriction. An attempt was made to find out 
whether  AET has any effect on the rate of disruption of 
mast cells following exposure to compound 48/80, an agent 
which causes histamine release.[36] It has been assumed that 
the process leading to histamine secretion may be mediated 
by calcium release from an intracellular store of mast   
cells.[37] In this study, T. baccata offered significant protection 
against compound 48/80 induced mast cell degranulation 
by stabilizing it, which is responsible for the decreasing 
airway inflammation by preventing the release of various 
inflammatory mediators.
Phytochemical screening of T. baccata showed the 
presence of lignans, flavonoids, sugar derivatives, etc.[38,39]
Lignans are known to possess various biological activities 
including antibacterial, antioxidant, anticancer, spasmolytic 
and anti-inflammatory effects.[40] Flavonoids are known to 
possess various biological activities including antibacterial, 
antifungal, spasmolytic, antiviral, anticancer, and anti-
inflammatory effects.[41-43] Anti-asthmatic activity of 
T. baccata may be due to the presence of the above 
constituents. In conclusion, our data suggest that the 
alcoholic extract of the leaves of T. baccata possesses 
significant anti-asthmatic activity and has beneficial effect 
in asthma by causing bronchorelaxation and decreasing 
bronchial hyperreactivity.
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